@jgfellow-nephro.bsky.social
Reposted
What is your diagnosis for this finding in a young patient with renal artery stenosis?
#DiagnoseThis #nephsky #pathsky #renal #kidneypath
#DiagnoseThis #nephsky #pathsky #renal #kidneypath
November 17, 2025 at 2:02 PM
What is your diagnosis for this finding in a young patient with renal artery stenosis?
#DiagnoseThis #nephsky #pathsky #renal #kidneypath
#DiagnoseThis #nephsky #pathsky #renal #kidneypath
Reposted
OK thread of all simulpubs at this year's #KidneyWk
ORIGIN-3: Atacicept pubmed.ncbi.nlm.nih.gov/41196369/
CKD as a curable dz? www.kidney-international.org/article/S008...
Albuminuria as a surrogate endpoint www.nature.com/articles/s41...
ORIGIN-3: Atacicept pubmed.ncbi.nlm.nih.gov/41196369/
CKD as a curable dz? www.kidney-international.org/article/S008...
Albuminuria as a surrogate endpoint www.nature.com/articles/s41...
November 9, 2025 at 11:30 PM
OK thread of all simulpubs at this year's #KidneyWk
ORIGIN-3: Atacicept pubmed.ncbi.nlm.nih.gov/41196369/
CKD as a curable dz? www.kidney-international.org/article/S008...
Albuminuria as a surrogate endpoint www.nature.com/articles/s41...
ORIGIN-3: Atacicept pubmed.ncbi.nlm.nih.gov/41196369/
CKD as a curable dz? www.kidney-international.org/article/S008...
Albuminuria as a surrogate endpoint www.nature.com/articles/s41...
Reposted
Shocking first high impact trial of the day. Fish oil reduces CV events in dialysis patients! #Pisces #kidneywk
Simultaneous pub in NEJM
www.nejm.org/doi/full/10....
Simultaneous pub in NEJM
www.nejm.org/doi/full/10....
November 7, 2025 at 4:45 PM
Shocking first high impact trial of the day. Fish oil reduces CV events in dialysis patients! #Pisces #kidneywk
Simultaneous pub in NEJM
www.nejm.org/doi/full/10....
Simultaneous pub in NEJM
www.nejm.org/doi/full/10....
Reposted
The BICAR-ICU-2 trial just dropped!
RCT involving IV bicarb in metabolic acidosis among patients with mod-severe AKI
Bicarb didn't affect mortality but it reduced the need for dialysis & risk of bacteremia
VERY similar conclusions to BICAR-ICU-1
🧵 #1/
jamanetwork.com/journals/jam... #EMIMCC
RCT involving IV bicarb in metabolic acidosis among patients with mod-severe AKI
Bicarb didn't affect mortality but it reduced the need for dialysis & risk of bacteremia
VERY similar conclusions to BICAR-ICU-1
🧵 #1/
jamanetwork.com/journals/jam... #EMIMCC
October 29, 2025 at 2:59 PM
The BICAR-ICU-2 trial just dropped!
RCT involving IV bicarb in metabolic acidosis among patients with mod-severe AKI
Bicarb didn't affect mortality but it reduced the need for dialysis & risk of bacteremia
VERY similar conclusions to BICAR-ICU-1
🧵 #1/
jamanetwork.com/journals/jam... #EMIMCC
RCT involving IV bicarb in metabolic acidosis among patients with mod-severe AKI
Bicarb didn't affect mortality but it reduced the need for dialysis & risk of bacteremia
VERY similar conclusions to BICAR-ICU-1
🧵 #1/
jamanetwork.com/journals/jam... #EMIMCC
Reposted
I think this was the expected finding based on the original BICAR-ICU trial. In that one, 52% of the control group received RRT (and therefore bicarb) with a mean of 7 hours from enrollment. With poor separation of treatment arms, it’s hard to attribute the mortality benefit to the intervention.
October 30, 2025 at 2:39 AM
I think this was the expected finding based on the original BICAR-ICU trial. In that one, 52% of the control group received RRT (and therefore bicarb) with a mean of 7 hours from enrollment. With poor separation of treatment arms, it’s hard to attribute the mortality benefit to the intervention.
Reposted
Gain-of-function mutation of H+ATPase (gene ATP6V0A4) linked to renal tubular ALKALOSIS. dm5migu4zj3pb.cloudfront.net/manuscripts/...
dm5migu4zj3pb.cloudfront.net
October 25, 2025 at 6:34 PM
Gain-of-function mutation of H+ATPase (gene ATP6V0A4) linked to renal tubular ALKALOSIS. dm5migu4zj3pb.cloudfront.net/manuscripts/...
Reposted
Renalism: The failure to perform appropriate diagnostic/ therapeutic interventions in patients with CKD due to concern about risk of AKI #Nephpearls #NephSky
👉🏼 pubmed.ncbi.nlm.nih.gov/15339996/
👉🏼 pubmed.ncbi.nlm.nih.gov/15339996/
October 24, 2025 at 7:42 AM
Renalism: The failure to perform appropriate diagnostic/ therapeutic interventions in patients with CKD due to concern about risk of AKI #Nephpearls #NephSky
👉🏼 pubmed.ncbi.nlm.nih.gov/15339996/
👉🏼 pubmed.ncbi.nlm.nih.gov/15339996/
Reposted
🚨NEW paper alert🚨 co-led by Fan Fan, Jane (Qian) Liu (from the zeelab.org), and an interdisciplinary, multi-institutional team using computational image analysis and machine learning methods to identify novel tubular features associated with clinical outcomes above and beyond known risk factors👇
October 3, 2025 at 12:58 AM
🚨NEW paper alert🚨 co-led by Fan Fan, Jane (Qian) Liu (from the zeelab.org), and an interdisciplinary, multi-institutional team using computational image analysis and machine learning methods to identify novel tubular features associated with clinical outcomes above and beyond known risk factors👇
Reposted
What is the name of the finding at the end of the arrow and what condition is it classically associated with?
#DiagnoseThis #pathology #renal #kidneypath #pathsky #nephsky
#DiagnoseThis #pathology #renal #kidneypath #pathsky #nephsky
September 29, 2025 at 1:04 PM
What is the name of the finding at the end of the arrow and what condition is it classically associated with?
#DiagnoseThis #pathology #renal #kidneypath #pathsky #nephsky
#DiagnoseThis #pathology #renal #kidneypath #pathsky #nephsky
Reposted
On September 18, @kdigo.org will release The 2025 Clinical Practice Guideline for the Management of IgA Nephropathy (IgAN) and IgA Vasculitis (IgAV)
#Nephpearls #NephSky
#Nephpearls #NephSky
September 15, 2025 at 5:29 PM
On September 18, @kdigo.org will release The 2025 Clinical Practice Guideline for the Management of IgA Nephropathy (IgAN) and IgA Vasculitis (IgAV)
#Nephpearls #NephSky
#Nephpearls #NephSky
Reposted
Have hyperglycemia (and other DM badness) been hiding in plain sight in ESKD?
Probably.
Great study using CGMs in ESKD.
Pts with treated DM, mean TIR only 43% while mean HbA1c was 7.0%
journals.lww.com/jasn/abstrac...
Probably.
Great study using CGMs in ESKD.
Pts with treated DM, mean TIR only 43% while mean HbA1c was 7.0%
journals.lww.com/jasn/abstrac...
Glycemia Assessed by Continuous Glucose Monitoring among... : Journal of the American Society of Nephrology
ilure and its treatments disrupt glucose homeostasis in ways that may promote both hyperglycemia and hypoglycemia. Continuous glucose monitoring (CGM) delineates detailed glycemic profiles, but publis...
journals.lww.com
September 13, 2025 at 7:16 PM
Have hyperglycemia (and other DM badness) been hiding in plain sight in ESKD?
Probably.
Great study using CGMs in ESKD.
Pts with treated DM, mean TIR only 43% while mean HbA1c was 7.0%
journals.lww.com/jasn/abstrac...
Probably.
Great study using CGMs in ESKD.
Pts with treated DM, mean TIR only 43% while mean HbA1c was 7.0%
journals.lww.com/jasn/abstrac...
Reposted
Real-world use of terlipressin in cirrhosis and acute kidney injury: frequent use beyond hepatorenal syndrome
#nephsky
www.sciencedirect.com/science/arti...
#nephsky
www.sciencedirect.com/science/arti...
Real-world use of terlipressin in cirrhosis and acute kidney injury: frequent use beyond hepatorenal syndrome
Terlipressin is indicated to treat hepatorenal syndrome (HRS)-acute kidney injury (AKI), but is likely used outside this primary indication in clinica…
www.sciencedirect.com
September 13, 2025 at 3:26 AM
Real-world use of terlipressin in cirrhosis and acute kidney injury: frequent use beyond hepatorenal syndrome
#nephsky
www.sciencedirect.com/science/arti...
#nephsky
www.sciencedirect.com/science/arti...
Reposted
Not just for albuminuria - flozination and co sequent glycosuria can result in interference for other biomarkers too
Albuminuria data: pubmed.ncbi.nlm.nih.gov/36736537/
Albuminuria data: pubmed.ncbi.nlm.nih.gov/36736537/
September 12, 2025 at 4:54 PM
Not just for albuminuria - flozination and co sequent glycosuria can result in interference for other biomarkers too
Albuminuria data: pubmed.ncbi.nlm.nih.gov/36736537/
Albuminuria data: pubmed.ncbi.nlm.nih.gov/36736537/
Reposted
Interesting pilot/feasibility trial in @kireports.bsky.social
Decremental dialysis in elderly patients with small inter dialytic weight gains - going from 3 to 2x week HD. Easy to recruit, good adherence.
www.kireports.org/article/S246...
Decremental dialysis in elderly patients with small inter dialytic weight gains - going from 3 to 2x week HD. Easy to recruit, good adherence.
www.kireports.org/article/S246...
September 4, 2025 at 1:04 AM
Interesting pilot/feasibility trial in @kireports.bsky.social
Decremental dialysis in elderly patients with small inter dialytic weight gains - going from 3 to 2x week HD. Easy to recruit, good adherence.
www.kireports.org/article/S246...
Decremental dialysis in elderly patients with small inter dialytic weight gains - going from 3 to 2x week HD. Easy to recruit, good adherence.
www.kireports.org/article/S246...
Reposted
Unlike most pathogenesis reviews which have multidirectional arrows or hypothesis based on 🐁 data
This @ndt-era.bsky.social review uses data from completed and ongoing trials to explain what we know about IgAN
academic.oup.com/ndt/advance-...
#NephSky #OpenAccess
This @ndt-era.bsky.social review uses data from completed and ongoing trials to explain what we know about IgAN
academic.oup.com/ndt/advance-...
#NephSky #OpenAccess
What do clinical trials teach us about the pathophysiology of human IgA nephropathy?
Abstract. Immunoglobulin A nephropathy (IgAN) is a primary glomerulonephritis characterized by IgA-dominant or co-dominant mesangial immune deposits seen o
academic.oup.com
September 9, 2025 at 12:33 AM
Unlike most pathogenesis reviews which have multidirectional arrows or hypothesis based on 🐁 data
This @ndt-era.bsky.social review uses data from completed and ongoing trials to explain what we know about IgAN
academic.oup.com/ndt/advance-...
#NephSky #OpenAccess
This @ndt-era.bsky.social review uses data from completed and ongoing trials to explain what we know about IgAN
academic.oup.com/ndt/advance-...
#NephSky #OpenAccess
Reposted
Paired nicely with the French ALCHEMIST trial (also negative)
www.thelancet.com/journals/lan...
#NephJC #NephSky
www.thelancet.com/journals/lan...
#NephJC #NephSky
Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-anal...
In patients with kidney failure on haemodialysis and with high risk of adverse cardiovascular
outcomes, spironolactone did not reduce the incidence of major cardiovascular events.
The updated meta-ana...
www.thelancet.com
August 15, 2025 at 1:59 AM
Paired nicely with the French ALCHEMIST trial (also negative)
www.thelancet.com/journals/lan...
#NephJC #NephSky
www.thelancet.com/journals/lan...
#NephJC #NephSky
Reposted
Spironolactone does not work for dialysis
ACHIEVE published in @thelancet.com
@lastwalsh.bsky.social and colleagues
www.thelancet.com/journals/lan...
Coming soon to a #NephJC near you
ACHIEVE published in @thelancet.com
@lastwalsh.bsky.social and colleagues
www.thelancet.com/journals/lan...
Coming soon to a #NephJC near you
Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial
Among patients receiving maintenance dialysis, spironolactone 25 mg daily orally did
not reduce the composite outcome of cardiovascular mortality and hospitalisation due
to heart failure compared with...
www.thelancet.com
August 14, 2025 at 11:15 PM
Spironolactone does not work for dialysis
ACHIEVE published in @thelancet.com
@lastwalsh.bsky.social and colleagues
www.thelancet.com/journals/lan...
Coming soon to a #NephJC near you
ACHIEVE published in @thelancet.com
@lastwalsh.bsky.social and colleagues
www.thelancet.com/journals/lan...
Coming soon to a #NephJC near you
Reposted
Diagnosis and Management of Osteoporosis in Advanced Kidney Disease: A Review ca. 2022 from @ajkd.bsky.social
#Nephpearls #NephSky
👉🏼 pubmed.ncbi.nlm.nih.gov/34419519/
#Nephpearls #NephSky
👉🏼 pubmed.ncbi.nlm.nih.gov/34419519/
August 10, 2025 at 10:25 PM
Diagnosis and Management of Osteoporosis in Advanced Kidney Disease: A Review ca. 2022 from @ajkd.bsky.social
#Nephpearls #NephSky
👉🏼 pubmed.ncbi.nlm.nih.gov/34419519/
#Nephpearls #NephSky
👉🏼 pubmed.ncbi.nlm.nih.gov/34419519/
Reposted
A bold guideline from the beginning!
“We suggest that all individuals with hypertension be screened for primary aldosteronism”
“We suggest that all individuals with hypertension be screened for primary aldosteronism”
July 16, 2025 at 10:52 PM
A bold guideline from the beginning!
“We suggest that all individuals with hypertension be screened for primary aldosteronism”
“We suggest that all individuals with hypertension be screened for primary aldosteronism”
Reposted
Finerenone gets the HFpEF nod from FDA - as expected
NephJC coverage of FINEHEARTS www.nephjc.com/news/fineheart
Our editorial on kidney outcomes from FINEARTS: pubmed.ncbi.nlm.nih.gov/39814475/
NephJC coverage of FINEHEARTS www.nephjc.com/news/fineheart
Our editorial on kidney outcomes from FINEARTS: pubmed.ncbi.nlm.nih.gov/39814475/
Re”FINE”ing the role of non steroidal MRAs in Cardio Kidney Metabolic syndrome — NephJC
This week, we will discuss non-steroidal mineralocorticoid antagonist in the multiverse of cardiovascular-kidney-metabolic. What FINEHEART pooled analysis would add to what we already learned from FID...
www.nephjc.com
July 14, 2025 at 6:40 PM
Finerenone gets the HFpEF nod from FDA - as expected
NephJC coverage of FINEHEARTS www.nephjc.com/news/fineheart
Our editorial on kidney outcomes from FINEARTS: pubmed.ncbi.nlm.nih.gov/39814475/
NephJC coverage of FINEHEARTS www.nephjc.com/news/fineheart
Our editorial on kidney outcomes from FINEARTS: pubmed.ncbi.nlm.nih.gov/39814475/
Reposted
PRECISION: In patients w/ resistant hypertension, aprocitentan was well tolerated & superior to placebo in lowering BP at week 4 w/ a sustained effect at week 40 ca. 2022 from @thelancet.com
#Nephpearls #NephSky
👉🏼 www.thelancet.com/journals/lan...
#Nephpearls #NephSky
👉🏼 www.thelancet.com/journals/lan...
June 20, 2025 at 12:41 AM
PRECISION: In patients w/ resistant hypertension, aprocitentan was well tolerated & superior to placebo in lowering BP at week 4 w/ a sustained effect at week 40 ca. 2022 from @thelancet.com
#Nephpearls #NephSky
👉🏼 www.thelancet.com/journals/lan...
#Nephpearls #NephSky
👉🏼 www.thelancet.com/journals/lan...
Reposted
This week at the Ottawa #NephGR
we have @vijayanmd.bsky.social from Intermountain Health on outpatient dialysis after AKI
#NephSky
we have @vijayanmd.bsky.social from Intermountain Health on outpatient dialysis after AKI
#NephSky
June 2, 2025 at 12:40 PM
This week at the Ottawa #NephGR
we have @vijayanmd.bsky.social from Intermountain Health on outpatient dialysis after AKI
#NephSky
we have @vijayanmd.bsky.social from Intermountain Health on outpatient dialysis after AKI
#NephSky
Reposted
Adrenal insufficiency is a syndrome of cortisol deficiency.
🎙️ In this podcast episode, listen to author Anand Vaidya discuss the pathophysiology, diagnosis, and treatment of adrenal insufficiency and adrenal crisis with JAMA Associate Editor David Simel.
🎧 Listen now:
🎙️ In this podcast episode, listen to author Anand Vaidya discuss the pathophysiology, diagnosis, and treatment of adrenal insufficiency and adrenal crisis with JAMA Associate Editor David Simel.
🎧 Listen now:
Adrenal Insufficiency in Adults
Adrenal insufficiency is a syndrome of cortisol deficiency. A recent JAMA Review summarizes the pathophysiology, diagnosis, and treatment of adrenal insufficiency and adrenal crisis. JAMA Associate Editor David Simel, MD, MHS, discusses this and more with author Anand Vaidya, MD, MMSc.
edhub.ama-assn.org
June 17, 2025 at 4:56 PM
Adrenal insufficiency is a syndrome of cortisol deficiency.
🎙️ In this podcast episode, listen to author Anand Vaidya discuss the pathophysiology, diagnosis, and treatment of adrenal insufficiency and adrenal crisis with JAMA Associate Editor David Simel.
🎧 Listen now:
🎙️ In this podcast episode, listen to author Anand Vaidya discuss the pathophysiology, diagnosis, and treatment of adrenal insufficiency and adrenal crisis with JAMA Associate Editor David Simel.
🎧 Listen now:
Reposted
Low risk of tac balanced out by real risk of infection and thrombosis in uncontrolled nephrotic syndrome. People forget that 80-90% of these kids died pre-steroid. #NephJC
June 11, 2025 at 2:00 AM
Low risk of tac balanced out by real risk of infection and thrombosis in uncontrolled nephrotic syndrome. People forget that 80-90% of these kids died pre-steroid. #NephJC
Reposted
Triple drug combo now available in US - approved by FDA
Telmisartan 10
Amlodipine 1.25
Indapamide 0.625
george-medicines.com/george-medic...
#Hypertension
#Widaplik
Also in higher doses:
20/2.5/1.25 and
40/5/2.5
Telmisartan 10
Amlodipine 1.25
Indapamide 0.625
george-medicines.com/george-medic...
#Hypertension
#Widaplik
Also in higher doses:
20/2.5/1.25 and
40/5/2.5
George Medicines announces FDA approval of WIDAPLIK™ (telmisartan, amlodipine and indapamide), a new single pill combination treatment for hypertension in adults, including initial treatment
Novel, single pill, triple combination with a standard dose and two lower doses that can deliver the efficacy benefits of combination therapy, with an established safety profile and good tolerability ...
george-medicines.com
June 9, 2025 at 10:53 PM
Triple drug combo now available in US - approved by FDA
Telmisartan 10
Amlodipine 1.25
Indapamide 0.625
george-medicines.com/george-medic...
#Hypertension
#Widaplik
Also in higher doses:
20/2.5/1.25 and
40/5/2.5
Telmisartan 10
Amlodipine 1.25
Indapamide 0.625
george-medicines.com/george-medic...
#Hypertension
#Widaplik
Also in higher doses:
20/2.5/1.25 and
40/5/2.5